Apoptosis, the programmed cell death pathway, plays a critical role in the pathogenesis of Alzheimer's disease (AD). While neuronal apoptosis is essential for normal brain development and homeostasis, dysregulated apoptosis contributes to the progressive loss of vulnerable neurons in AD. This page provides a comprehensive overview of the intrinsic (mitochondrial) and extrinsic (death receptor) apoptosis pathways, their specific alterations in AD, and the key molecular players that drive neuronal death in this devastating disease.
Neuronal apoptosis in AD is characterized by the activation of both intrinsic and extrinsic cell death pathways, driven by multiple pathological insults including amyloid-beta accumulation, tau pathology, mitochondrial dysfunction, oxidative stress, and neuroinflammation (Mattson, 2000). The activation of apoptotic cascades represents a final common pathway through which these diverse insults lead to synaptic loss and neuronal death[1].
The two major apoptosis pathways—the intrinsic (mitochondrial) pathway and the extrinsic (death receptor) pathway—converge on the activation of effector caspases that execute the cellular demolition program. Understanding these pathways in the context of AD provides insights into potential therapeutic interventions aimed at preventing or slowing neuronal loss[2].
The intrinsic apoptosis pathway is triggered by intracellular stress signals and is regulated by the BCL-2 family of proteins. In AD, multiple pathological stimuli activate this pathway[3]:
The pivotal event in intrinsic apoptosis is mitochondrial outer membrane permeabilization (MOMP), which releases pro-apoptotic proteins from the intermembrane space into the cytosol. Key proteins released include[4]:
MOMP is regulated by the balance between pro-apoptotic and anti-apoptotic BCL-2 family proteins[5].
The extrinsic apoptosis pathway is activated by extracellular ligands binding to death receptors on the cell surface. In AD, several death receptor pathways are implicated[6]:
The p75 neurotrophin receptor (p75NTR) can mediate apoptosis in neurons expressing its ligands (pro-BDNF, pro-NGF). In AD, p75NTR expression is altered and contributes to neuronal vulnerability (Ibanez & Simi, 2012)[7].
Caspases are cysteine proteases that execute apoptosis. The caspase cascade in AD involves[8]:
Caspase activation has been documented in AD brain tissue, with increased activity of caspase-3, caspase-8, and caspase-9 in vulnerable neuronal populations (Rohn et al., 2001)[9].
The BCL-2 family consists of anti-apoptotic (BCL-2, BCL-XL, MCL-1, BCL-W) and pro-apoptotic (BAX, BAK, BAD, BID, BIM, PUMA, NOXA) members that regulate MOMP[10].
The balance between these proteins is critical: elevated BAX/BAK with decreased BCL-2 promotes MOMP and neuronal death in AD[19].
The tumor suppressor p53 is a key regulator of apoptosis and is implicated in AD pathogenesis[20]:
Apoptosis in AD is tightly linked to other key pathological mechanisms[21]:
Understanding apoptosis pathways in AD has led to therapeutic strategies[15:1][16:1][18:1]:
Research on neuroprotective strategies for AD has identified several promising approaches[23]:
Caspase inhibitors have demonstrated neuroprotective effects in AD models[26]: Aβ-induced neuronal apoptosis was significantly reduced in primary cortical neurons treated with caspase-3 inhibitors, and in vivo studies in AD mouse models showed reduced neuronal loss and improved cognitive performance[12:1].
The XIAP (X-linked inhibitor of apoptosis) protein is a key endogenous caspase inhibitor, and overexpression of XIAP protects neurons from Aβ-induced apoptosis[19:2]. Small molecule BCL-2 modulators that shift the balance toward anti-apoptotic proteins are being developed as potential AD therapeutics[15:2].
Mitochondrial permeability transition pore (mPTP) opening is a critical event in Aβ-induced neuronal death[9:2][27], and cyclophilin D inhibitors that prevent mPTP opening represent a novel neuroprotective strategy. Additionally, p53 aggregation in AD neurons contributes to gain-of-function toxicity, and approaches to prevent p53 aggregation are under investigation[2:1].
Copani A et al. DNA damage and p53 in neurodegeneration. Brain Res Rev. 2006. ↩︎
Sumbria RK et al. p53 aggregation in Alzheimer's disease. Nat Commun. 2023. ↩︎ ↩︎
Yuan J et al. Apoptosis and beyond: cell death in AD. Neuron. 2023. ↩︎
Bredesen DE. Multiple apoptotic pathways in AD. J Alzheimers Dis. 2016. ↩︎
Obulesu M et al. Apoptosis in Alzheimer's disease. J Neurosci Res. 2011. ↩︎
Wang X et al. Cytochrome c release in AD. J Neurochem. 2019. ↩︎
Reddy PH et al. BAX/BCL-2 ratio in AD. J Alzheimers Dis. 2020. ↩︎
Fadeel B et al. Apoptosis-inducing factor in neurodegeneration. Cell Death Differ. 2019. ↩︎
Sullivan PG et al. Mitochondrial permeability transition in AD. Neurobiol Dis. 2021. ↩︎ ↩︎ ↩︎
Elmore SP et al. The role of SMAC/DIABLO in apoptosis. Cell Signal. 2020. ↩︎
Kelley JB et al. Caspase-9 activation in Alzheimer's disease. Brain Pathol. 2021. ↩︎
Yuan J et al. Caspase-2 and caspase-3 in AD. J Clin Invest. 2020. ↩︎ ↩︎
Gustafsson AB et al. BCL-2 family interactions in mitochondria. Nat Rev Mol Cell Biol. 2022. ↩︎
Miller DW et al. p75NTR and amyloid toxicity. Exp Neurol. 2015. ↩︎
Longo FM et al. Small molecule BCL-2 modulators in AD. Pharmacol Res. 2020. ↩︎ ↩︎ ↩︎
O'Brien RJ et al. Caspase inhibitors in AD therapy. Nat Rev Drug Discov. 2021. ↩︎ ↩︎
Friedman E et al. Mitochondrial dysfunction in AD: therapeutic approaches. J Geriatr Psychiatry Neurol. 2022. ↩︎
Mattson MP et al. Neuroprotective strategies for AD. Trends Neurosci. 2019. ↩︎ ↩︎
Patterson B et al. XIAP and caspase inhibition in AD. Cell Death Discov. 2021. ↩︎ ↩︎ ↩︎
Kalkavan H et al. MOMP in neuronal death. Cell Rep. 2022. ↩︎
Galluzzi L et al. Molecular mechanisms of cell death. Cell Death Differ. 2018. ↩︎
Shimohama S et al. Fas-mediated apoptosis in AD. Brain Res. 2001. ↩︎
Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Neurosci. 2000. ↩︎
Butterfield DA et al. Role of oxidative stress in Alzheimer's disease. Brain Res. 2002. ↩︎
Heneka MT et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2013. ↩︎
Rohn TT et al. Caspase activation in Alzheimer's disease. J Neurosci Res. 2001. ↩︎
Bernardi P et al. The mitochondrial permeability transition pore. J Mol Cell Cardiol. 2022. ↩︎